Michael Charlton to Liver Neoplasms
This is a "connection" page, showing publications Michael Charlton has written about Liver Neoplasms.
Connection Strength
4.441
-
Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology. 2020 07; 72(1):315-329.
Score: 0.473
-
Liver Allocation Policies in the USA: Past, Present, and the Future. Dig Dis Sci. 2019 04; 64(4):985-992.
Score: 0.434
-
The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis. Hepatology. 2019 03; 69(3):931-933.
Score: 0.431
-
Liver Transplantation for Nonalcoholic Steatohepatitis: New Evidence of a Profound Increase Across Age Cohorts. Transplantation. 2019 01; 103(1):1-2.
Score: 0.427
-
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clin Liver Dis. 2018 02; 22(1):201-211.
Score: 0.400
-
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology. 2017 04; 152(5):1090-1099.e1.
Score: 0.372
-
Lack of Survival Benefit Following Liver Transplantation With MELD Exception Points for Hepatocellular Carcinoma: Beyond the Unblinding of Lady Justice. Gastroenterology. 2015 Sep; 149(3):531-4.
Score: 0.336
-
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015 Jan; 148(1):108-17.
Score: 0.318
-
Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. Am J Transplant. 2014 Jun; 14(6):1383-90.
Score: 0.309
-
The lethal and enduring inequity of deceased donor liver allocation policy for hepatocellular carcinoma in the United States. Am J Transplant. 2013 Nov; 13(11):2794-6.
Score: 0.296
-
Liver Transplantation 2023: Status Report, Current and Future Challenges. Clin Gastroenterol Hepatol. 2023 07; 21(8):2150-2166.
Score: 0.144
-
Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol. 2018 Mar 28; 24(12):1321-1331.
Score: 0.101
-
Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 May; 21(5):599-606.
Score: 0.083
-
Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation. Liver Transpl. 2015 Feb; 21(2):248-57.
Score: 0.081
-
Branched-chain amino acids as pharmacological nutrients in chronic liver disease. Hepatology. 2011 Sep 02; 54(3):1063-70.
Score: 0.063
-
The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007 Mar; 5(3):394-402; quiz 267.
Score: 0.047
-
Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis? Nat Clin Pract Gastroenterol Hepatol. 2006 Feb; 3(2):72-3.
Score: 0.044
-
Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis. Hum Pathol. 2002 Apr; 33(4):435-6.
Score: 0.033
-
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. Transplantation. 2017 05; 101(5):945-955.
Score: 0.024
-
Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival. Transpl Int. 2013 Aug; 26(8):788-94.
Score: 0.018
-
Clinical significance of TT virus infection in patients with chronic hepatitis C. Am J Gastroenterol. 1999 Oct; 94(10):3020-7.
Score: 0.007